Co-founder, Prisca is a trained biochemist who obtained her PhD in 2004 from the Freie Universität Berlin (Germany), focusing on peptide-based inhibitors of protein–protein interactions. She completed a postdoctoral fellowship in peptide vectors for therapeutic delivery at the University of Montpellier before joining the CNRS as a research scientist. Her expertise is supported by 57 publications, 5 book chapters, and 4 patents, with additional experience in myocardial infarction (MI) biotech. Prisca leads the company’s technological strategy and innovation, dedicated to developing advanced therapeutic solutions.